Saudi Arabia

Based on 2011 reported data

Based on 2011 reported data

I. Epidemiological profile

Population (UN Population Division)	2012	%
Number of active foci	68	
Number of people living within active foci	2 300 000	8
Number of people living in malaria-free areas	26 000 000	92
Total	28 300 000	

Parasites and vectors

Major plasmodium species:	*P. falciparum* (100%), *P. vivax* (0%)
Major anopheles species:	*An.arabiensis, sergentii, funestus, bacroftii, albimanus, balabacensis*

Programme phase: Elimination

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	1980
	ITNs/LLINs distributed to all age groups	Yes	1980
IRS	IRS is recommended	Yes	–
	DDT is used for IRS	No	–
Larval control	Use of larval control	Yes	–
IPT	IPT used to prevent malaria during pregnancy	N/A	–
Diagnosis	Patients of all ages should receive diagnostic test	Yes	–
	Malaria diagnosis is free of charge in the public sector	Yes	1963
Treatment	ACT is free for all ages in public sector	–	–
	Artemisinin-based monotherapies withdrawn	Yes	–
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for *P. falciparum*	Yes	1985
	Primaquine is used for radical treatment of *P. vivax*	No	–
	G6PD test is a requirement before treatment with primaquine	Yes	1985
	Directly observed treatment with primaquine is undertaken	No	–
	System for monitoring of adverse reaction to antimalarials exists	Yes	1990

Intervention	Policies/strategies	Yes/No	Year adopted
Surveillance	ACD for case investigation (reactive)	Yes	1980
	ACD at community level of febrile cases (pro-active)	Yes	1980
	Mass screening is undertaken	No	–
	Uncomplicated *P. falciparum* cases routinely admitted	No	–
	Uncomplicated *P. vivax* cases routinely admitted	No	–
	Foci and case investigation undertaken	Yes	1990
	Case reporting from private sector is mandatory	Yes	1990

Antimalaria treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	–	–
First-line treatment of *P. falciparum*	AS+SP	–
For treatment failure *of P. falciparum*	AL	–
Treatment of severe malaria	AS; AM; QN	–
Treatment of *P. vivax*	CQ+PQ(14d)	–
Dosage of primaquine for radical treatment of *P. vivax*		–

Therapeutic efficacy tests (clinical and parasitological failure, %)

Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species

III. Financing

Sources of financing



Expenditure by intervention in 2012

- Insecticides & spray materials
- ITNs
- Diagnostic testing
- Antimalarial medicines
- Monitoring and evaluation
- Human resources & technical assistance
- Management and other costs

No data reported for 2012

IV. Coverage

Coverage of ITNs and IRS



Cases tested and potentially treated (public sector)



V. Impact

Malaria test positivity rate and ABER



Proportion of malaria cases due to *P. vivax*

Malaria cases by source



Indigenous malaria cases by species



Impact: On track for >75% decrease in incidence 2000–2015